Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Qiagen ( (QGEN) ).
Qiagen has disclosed a manager’s transaction involving supervisory board member Elizabeth Tallett, in line with regulatory requirements under Article 19 of the Market Abuse Regulation. The transaction centers on the vesting and settlement of restricted stock units rather than an open-market share purchase or sale, and was executed outside a trading venue.
Tallett received the release of 5,990 restricted stock units from a 2025 grant and 3,166 units from a 2023 grant, with subsequent net share settlement resulting in the delivery of 4,713 common shares after withholding some shares to cover taxes and related costs. The move reflects routine equity-based compensation for senior governance members and signals ongoing reliance on stock-based incentives to align management and board interests with those of shareholders.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based biotechnology company that develops and supplies sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. Its shares are listed on several European exchanges as well as on the NYSE and Swiss markets, reflecting a broad international investor base.
Average Trading Volume: 2,173,009
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.1B
See more data about QGEN stock on TipRanks’ Stock Analysis page.